Bicycle Therapeutics Reports Q2 2025 Financial Results

Bicycle Therapeutics ( (BCYC) ) has released its Q2 earnings. Here is a breakdown of the information Bicycle Therapeutics presented to its investors.

Bicycle Therapeutics is a clinical-stage pharmaceutical company focused on developing a novel class of medicines known as Bicycle molecules, which are designed to address diseases underserved by existing therapeutics. The company operates in the biotechnology sector and is known for its proprietary bicyclic peptide technology.

In its latest earnings report, Bicycle Therapeutics highlighted significant progress in its research and development pipeline, with ongoing trials and strategic organizational changes. The company reported a cash position of $721.5 million as of June 30, 2025, and announced a strategic cost realignment to extend its financial runway into 2028.

Key financial metrics revealed an increase in research and development expenses to $71 million for the second quarter of 2025, driven by the development of zelenectide pevedotin. General and administrative expenses also rose to $18.5 million. The company reported a net loss of $79 million for the quarter, reflecting increased investment in clinical programs.

Strategically, Bicycle Therapeutics has strengthened its leadership team and formed a new Research and Innovation Advisory Board to support its growth. The company is actively recruiting for its Phase 1/2 Duravelo-4 trial and plans to provide updates on its clinical programs in the coming months.

Looking ahead, Bicycle Therapeutics remains focused on advancing its pipeline and achieving key milestones, supported by its disciplined capital allocation and strategic cost management. The company aims to continue delivering value-generating datasets and maintaining operational flexibility in a challenging market environment.